Alteration of tumor necrosis factor-α T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome

Blood

Volumn 95, Issue 10, 2000, Pages 3191-3198

  Ledru, Eric ^b   Christeff, Névéna ^b   Patey, Olivier ^b   De Truchis, Pierre ^b   Melchior, Jean Claude ^b   Gougeon, Marie Lise ^a  

^a INSTITUT PASTEUR   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN B; CD8 ANTIGEN; CHOLESTEROL; DIDANOSINE; INDINAVIR; INTERLEUKIN 2; LAMIVUDINE; STAVUDINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG MECHANISM; DYSLIPIDEMIA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOMODULATION; LIPID METABOLISM; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0034657296     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.10.3191     Document Type: Article

References (56)

1. Pakker NG, Nolermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med. 1998;4:208.
2. Bohler T, Walcher J, Holzl-Wenig G, et al. Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents. AIDS. 1999;13:779.
3. Gougeon ML, Lecoeur H, Sasaki Y. Apoptosis and the CD95 system in HIV disease: impact of highly active anti-retroviral therapy (HAART). Immunol Lett. 1999;66:97.
4. Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold FF, Young NS. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood. 1999;94:1021.
5. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999;5:83.
6. Douek DC, McFartand RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998; 396:690.
7. Zhang LQ, Lewin SR, Markowitz M, et al. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med. 1999;190:725.
8. Autran B, Carcelain G, Li T, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112.
9. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 1998;4:953.
10. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1 specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 1999; 5:518.
11. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 1997;3:533.
12. Gorochov G, Neumann AU, Kereveur A, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med. 1998;4:215.
13. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for life-long persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512.
14. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS, 1998;12:F37.
15. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871.
16. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51.
17. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805.
18. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 1998;351:867.
19. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller I. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS. 1999;13:735.
20. Christeff N, Melchior JC, deTruchis P, Peronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormones alterations. AIDS. 1999;13:2251.
21. Sullivan AK, Nelson MR, Moyle GJ, Newell AM, Feher MD, Gazzard BG. Coronary artery disease occurring with protease inhibitor therapy. Int J STD AIDS. 1998;9:711.
22. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351:1328.
23. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 -protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881.
24. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112.
25. Feingold KR, Serio MK, Adi S, Moser AH, Grunfeld C. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology. 1989;124:2336.
26. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad of Sci U S A. 1994;91:4854.
27. Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon ML. Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J Immunol. 1998;160:3194.
28. Lecoeur H, Ledru E, Gougeon ML. A method for the simultaneous detection of both intracellular and surface antigens of apoptotic peripheral lymphocytes. J Immunol Methods. 1998;217:11.
29. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med. 1998;188:83.
30. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptosis. Nature. 1997;390:350.
31. Gougeon ML, Garcia S, Heeney J, et al. Programmed cell death in AIDS-related HIV and SIV infections. Aids Res Hum Retroviruses. 1993;9:553.
32. Karavellas MP, Plummer DJ, MacDonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis. 1999;179:697.
33. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet. 1998;351:252.
34. Foudraine NA, Hovenkamp E, Notermans DW, et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 1999;13:177.
35. Roulston A, Lin R, Beauparlant P, Wainberg MA, Hiscott J. Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kB/rel transcription factors. Microbiol Rev. 1995;59:481.
36. Douni E, Kollias G. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin α, or the p55TNF-R. J Exp Med. 1998;188:1343.
37. Baer M, Dillner A, Schwartz RC, Sedon C, Nedospasov S, Johnson PF. Tumor necrosis factor alpha transcription in macrophages is attenuated by an autocrine factor that preferentially induces NF-kappa B p50. Mol Cell Biol. 1998;18:5678.
38. Ruckdeschel K, Harb S, Roggenkamp A, et al. Yersinia enterocolitica Impairs activation of transcription factor NF-κB: involvement in the induction of programmed cell death and in the suppression of the macrophage tumor necrosis factor α production. J Exp Med. 1998;187:1069.
39. Orteu CH, Poulter LW, Rustin MHA, Sabin CA, Salmon M, Akbar AN. The role of apoptosis in the resolution of T cell-mediated cutaneous inflammation. J Immunol. 1998;161:1619.
40. Gougeon ML, Lecoeur H, Dulioust A, et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol. 1996;156:3509.
41. Banda NK, Bernier J, Kurahara DK, et al. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med. 1992;176:1099.
42. Herbein G, Mahlknecht U, Batliwalla F, et al. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature. 1998;395:189.
43. Andre P, Groettrup M, Klenerman P, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A. 1998;95:13,120.
44. Zhou YT, Wang ZW, Higa M, Newgard CB, Lingers RH. Reversing adipocyte differentiation: implications for treatment of obesity. Proc Natl Acad Sci U S A. 1999;96:2391.
45. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988;53:45.
46. Coeshott C, Ohnemus C, Pilyavskaya A, et al. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1 beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci U S A. 1999;96:6261.
47. Stambe C, Wicks IP. TNFalpha and response of treatment-resistant adult-onset Still's disease to thalidomide. Lancet. 1998;352:544.
48. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS. 1999; 13:2261-2267.
49. Prins JB, Niesler CU, Winterford CM, et al. Tumor necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes. 1997;46:1939.
50. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87.
51. Fernandez-Real JM, Molina A, Broch M, et al. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. Diabetes. 1999;48:1108.
52. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr. 1994;7:1149.
53. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr. 1999;20:228.
54. Suzuki T, Suzuki N, Engleman EG, Mizushima Y, Sakane T. Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1995; 99:251.
55. Corcoran C, Grinspoon S. Treatments for wasting in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1999;340:1740.
56. Christeff N, Melchior JC, Mammes O, Gherbi N, Dalle MT, Nunez EA. Correlation between increased cortisol:DHEA ratio and malnutrition in HIV-positive men. Nutrition. 1999;15:534.